Aethlon Medical

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices. Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices

Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday, February 14, 2024.

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR Jim Frakes - Interim CEO and CFO Steven LaRosa - CMO Guy Cipriani - COO Conference Call Participants Marla Marin - Zacks Thomas McGovern - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call.

Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Call Transcript

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments.

Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A.

Aethlon Medical Announces Appointment of James B. Frakes, M.B.A.

SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023

SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. The trial is expected to begin following completion of an internal in vitro binding study of relevant targets, and subsequent approval by the respective Ethics Boards of interested sites in India.

Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology

SAN DIEGO , Oct. 4, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, effective at 5:00 p.m. ET on October 4, 2023.

Aethlon Announces Reverse Stock Split

SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that Steven LaRosa, M.D., Chief Medical Officer, and James Frakes, Chief Financial Officer, will present a company overview on Tuesday, September 12 at 4:30 PM EST, during the H.C.

Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jim Frakes – Chief Financial Officer Charles J. Fisher, Jr. – Chief Executive Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Vernon Bernardino – H.C.

Aethlon Medical, Inc. (AEMD) Q1 2024 Earnings Call Transcript

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 10, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2023 and provided an update on recent developments.

Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Aug. 3, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it will issue financial results for its first quarter ended June 30, 2023, at 4:15 p.m. EST on Thursday, August 10, 2023.

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023

Proof-of-Concept Studies to Support the Use of the Hemopurifier  in the Ex Vivo Organ Perfusion Circuit SAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has signed a Collaboration Agreement with 34 Lives, PBC, to investigate the use of Aethlon's proprietary Hemopurifier® technology and 34 Lives' organ evaluation and preservation system, with the goal of increasing the supply of useable donated kidneys for human transplant. Financial terms of the agreement were not disclosed.

Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant

SAN DIEGO , July 6, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced the appointment of Nicolas Gikakis to its Board of Directors (Board), effective July 3, 2023. Mr. Gikakis will also serve as a member of the Nominating and Corporate Governance Committee of the Board.

Aethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2023 Earnings Conference Call June 28, 2023 4:30 PM ET Company Participants Jim Frakes - CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Jeremy Pearlman - Maxim Group Operator Good day, and welcome to the Aethlon Medical Fiscal Year End 2023 Earnings and Corporate Update Conference Call. [Operator Instructions] Please note, this event is being recorded.

Aethlon Medical, Inc. (AEMD) Q4 2023 Earnings Call Transcript

Conference Call to be Held Today at 4:30pm ET SAN DIEGO , June 28, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2023 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood.

Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

SAN DIEGO , June 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it will issue financial results for its fourth quarter ended March 31, 2023, at 4:15 p.m. EST on Wednesday, June 28, 2023.

Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023

Research to Confirm the Hemopurifier's Ability to Remove Harmful Viruses and Exosomes From Harvested Organs SAN DIEGO , June 21, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is investigating the use of its Hemopurifier® in the organ transplant market, in addition to its ongoing studies in cancer and COVID-19. "Our objective is to confirm that the Hemopurifier, in our translational studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from harvested organs," stated Charles J.

Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation

SAN DIEGO , June 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Charles J. Fisher, Jr. M.D.

Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest

SAN DIEGO , June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT. Management will also be participating in one-on-one meetings with investors at this conference being held June 6-8, 2023, in Los Angeles, California.

Aethlon Medical to Present at the 13th Annual LD Micro Invitational

SAN DIEGO , May 22, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier® to treat severe COVID-19 in India. MAMC was established in 1958 and is located in New Delhi, India.

Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India

Mangoceuticals Inc

Nordic American Tankers

Onconova Therapeutics

Tingo Group Inc

Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.

5 Hot Penny Stocks To Watch With The Stock Market Down This Week

CNS Pharmaceuticals

Getaround Inc

Use these tips for trading penny stocks efficiently The post Essential Penny Stock Trading Tools: Maximizing Efficiency appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Aethlon Medical Stock (AEMD)